Our global presence
Our global presence
In 2023, Pierre Fabre Laboratories generated 70% of its revenue from international sales; a 15-point increase in 10 years. This dynamic growth is driven by new product launches, our ability to adapt to the needs of patients and consumers in every country, and long-standing partnerships with local healthcare professionals.
Americas
11 % of Pierre Fabre's revenue
Dermo-cosmetics: 86 %
Oncology: 1 %
Dermatology: 6 %
Other drugs: 7 %
France
38 % of Pierre Fabre's revenue
Dermo-cosmetics: 57 %
Oncology: 5 %
Dermatology: 8 %
Other drugs: 30 %
europe (other than france)
31 % of Pierre Fabre's revenue
Dermo-cosmetics: 52 %
Oncology: 25 %
Dermatology: 7 %
Autres médicaments : 16 %
Africa,
Middle-East, Turkey
6 % of Pierre Fabre's revenue
Dermo-cosmetics: 42 %
Oncology: 10 %
Dermatology: 18 %
Other drugs: 30 %
Asia,
Pacific
31 % of Pierre Fabre's revenue
Dermo-cosmetics: 65 %
Oncology: 31 %
Dermatology: 1 %
Other drugs: 3 %
Mexico : A successful launch for Darrow
Offering a broad range of dermo- cosmetic products aimed at darker skin types and their needs. Their formulas are developed at the Innovation Center in Rio de Janeiro. Darrow is one of the top three brands prescribed by Brazilian dermatologists.
In 2023, Pierre Fabre launched this brand in Mexico, keeping its fundamental features, such as outstanding value for money, with one or two adjustments tailored to the preferences of Mexican consumers. The launch was a great success, boosted by an influencer marketing strategy and partnerships with Mexican healthcare professionals (dermatologists and pharmacists who are active within their community and/or on social media). In 2023, accounting for Brazil and Mexico, Darrow increased its net sales by almost 30%.
United States : Building ties with dermatologists
In 2023, Eau Thermale Avène grew at a record rate in the US. This unprecedented growth is down to the extension of its distribution network and a stronger social media presence, along with deeper ties between Pierre Fabre and American dermatologists.
A number of them were invited to take a tour of the Avène Hydrotherapy Center. This was a precious opportunity to meet the brand’s medical experts and discuss skin pathologies and how they are cared for at the Hydrotherapy Center.
In November 2023, the company also acquired marketing rights in the US for a revolutionary cell therapy aimed at patients suffering from an Epstein-Barr virus-positive post- transplant lymphoproliferative disease. That project led to the creation of a new Medical Care subsidiary in the country, prompting the formation of a team specialized in oncology.
Poland : Commitment to healthcare professionals
In Poland, the subsidiary continued its efforts to build close ties with healthcare professionals and scientific societies.
The teams took part in campaigns to raise awareness about melanoma, organized by the Polish Society of Oncology, particularly by getting involved in the “Run away from melanoma” charity race. In 2023, the dermocosmetics business posted double-digit growth, driven by influencer marketing, omnichannel communication and distribution, and recommendations from healthcare professionals. The Dexeryl brand and Cicalfate range by Avène, for example, were presented to Polish pediatricians to help them treat babies with dry and irritated skin.
China : Promoting innovation
In China, the cost of oncology research and treatment for continues to rise considerably. By way of example, the country accounts for 24% of all breast cancer cases diagnosed world- wide each year*. Pierre Fabre Laboratories is working with the scientific community to enhance available treatments for those cancers. In 2023, 6,500 Chinese women were treated with Nerlynx, a targeted therapy prescribed to prevent breast cancer relapse.
In parallel, Pierre Fabre is conducting clinical trials to address certain forms of lung and colorectal cancer. A research fund has also been launched in partnership with CSCO, the Chinese Society of Clinical Oncology. In the field of dermo-cosmetics, our China Innovation Center, which opened in 2023, also focuses on developing products and formulas tailored to the needs of Chinese consumers.
*Mei Zhang, Heling Bao, Xiao Zhang, Zhengjing Huang, Zhenping Zhao, Chun Li, Maigeng Zhou, Jing Wu, Limin Wang, Linhong Wang. Breast Cancer Screening Coverage — China, 2018–2019[J]. China CDC Weekly, 2023, 5(15): 321-326. doi: 10.46234/ccdcw2023.062
